Ventracor: VentrAssist bridge-to-transplant trial data show 83% success rate

By E. Janene Geiss

Philadelphia, Sept. 12 - Ventracor said Tuesday that clinical results of the VentrAssist left ventricular assist device CE Mark bridge-to-transplant trial showed 83% success rate, which is significantly better than the earlier published results of first generation devices reported to be 65%.

The trial's endpoint was cardiac transplant or continued transplant eligible at 154 days after a VentrAssist implant, the Chatswood, Australia, medical device company said in a news release.

The adverse event rate was in line with expectations, officials said. The results were presented at a meeting of the European Association of Cardiothoracic Surgeons in Sweden this week.

The data will be included in a report that will be submitted soon as part of the CE Mark approval process. The company said it hopes to begin selling the device in Europe with a CE Mark in early 2007.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.